Home » Newsletters » BioWorld

BioWorld

Aug. 16, 1991

View Archived Issues

PATENT

DYNAGEN EXERCISES WARRANTS, RAISES $2.35M

ONCOGENE COMPLETES PURCHASE OF AbT CANCER BUSINESS

INSURANCE FIRM ACQUIRES STAKE IN XYTRONYX

COLUMBIA LABS RAISES $12M IN PRIVATE PLACEMENT

KODAK SEEKS INJUNCTION AGAINST CETUS

ANALYST RECOMMENDS TAKING PROFITS ON ICOS

MIMETICS MAY HERALD A NEW CLASS OF DRUGS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.